Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Journal of Evaluation in Clinical Practice

Volumn 19, Issue 1, 2013, Pages 50-59

  Xu, Yihua ^f   Viswanathan, Hema N ^a   Ward, Melea A ^b   Clay, Brad ^f   Adams, John L ^c   Stolshek, Bradley S ^b   Kallich, Joel D ^d   Fine, Shari ^e   Saag, Kenneth G ^f  

^a Research Scientist   (United States)

^b AMGEN INC   (United States)

^c RAND CORPORATION   (United States)

^d HUMANA INC   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama ^*

Author keywords

bisphosphonates; discontinuation; osteoporosis; osteoporosis treatment; switching

Indexed keywords

ALENDRONIC ACID; CALCITONIN; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 84872958625     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2011.01766.x     Document Type: Article

References (19)

1. The National Osteoporosis Foundation (2011) Fast facts. Available at: http://www.nof.org/node/40 (last accessed 2 June 2011).
2. National Center for Health Statistics (2002) National Health and Nutrition Examination Survey III-Osteoporosis. Hyattsville, MD: Public Health Service. Available at: http://www.cdc.gov/nchs/data/nhanes/databriefs/ osteoporosis.pdf (last accessed 2 June 2011).
3. US Department of Health and Human Service (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General. Available at: http://www.surgeongeneral.gov/library/bonehealth/content.html (last accessed 2 June 2011).
4. McCombs, J. S., Thiebaud, P., McLaughlin-Miley, C., &, Shi, J., (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 48, 271-287. (Pubitemid 38781153)
5. Segal, E., Tamir, A., &, Ish-Shalom, S., (2003) Compliance of osteoporotic patients with different treatment regimens. The Israel Medical Association Journal, 5, 859-862. (Pubitemid 38008106)
6. Tosteson, A. N., Grove, M. R., Hammond, C. S., Moncur, M. M., Ray, G. T., Hebert, G. M., Pressman, A. R., &, Ettinger, B., (2003) Early discontinuation of treatment for osteoporosis. The American Journal of Medicine, 115, 209-216. (Pubitemid 37338146)
7. Cooper, A., Drake, J., &, Brankin, E., (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. International Journal of Clinical Practice, 60, 896-905. (Pubitemid 44082279)
8. Tosteson, A. N., Do, T. P., Wade, S. W., Anthony, M. S., &, Downs, R. W., (1769) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporosis International, 21, 1769 -1780.
9. Huybrechts, K. F., Ishak, K. J., &, Caro, J. J., (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone, 38, 922-928. (Pubitemid 44498580)
10. Imaz, I., Zegarra, P., Gonzalez-Enriquez, J., Rubio, B., Alcazar, R., &, Amate, J. M., (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International, 21, 1943-1951.
11. Kothawala, P., Badamgarav, E., Ryu, S., Miller, R. M., &, Halbert, R. J., (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clinic Proceedings, 82, 1493-1501. (Pubitemid 350211697)
12. Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., &, Silverman, S., (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings, 81, 1013-1022. (Pubitemid 44175011)
13. Centers for Medicare & Medicaid Services (2009) Medicare managed care manual. Available at: http://www.cms.gov/MedicareMangCareEligEnrol/Downloads/ MAEnrollmentGuidanceUpdateFINAL2010.pdf (last accessed 2 June 2011).
14. Ryzner, K. L., Burkiewicz, J. S., Griffin, B. L., &, Komperda, K. E., (2010) Survey of bisphosphonate regimen preferences in an urban community health center. The Consultant Pharmacist, 25, 671-675.
15. Simon, J. A., Lewiecki, E. M., Smith, M. E., Petruschke, R. A., Wang, L., &, Palmisano, J. J., (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clinical Therapeutics, 24, 1871-1886. (Pubitemid 35440956)
16. Gold, D. T., Trinh, H., &, Safi, W., (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Current Medical Research and Opinion, 25 (8), 1831-1839.
17. Lewiecki, E. M., (2011) Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs, 71, 791-814.
18. Rizzoli, R., (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM, 104, 281-300.
19. Medicare Fact Sheet (2010) Medicare Advantage. Available at: http://www.kff.org/medicare/upload/2052-14.pdf (last accessed 22 June 2011).